# Biostar Pharmaceuticals, Inc. (BSPM)

> Source: Nexqual · https://nexqual.com/BSPM · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Biostar Pharmaceuticals, Inc. (BSPM), nexqual.com/BSPM" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 22, 2026; US market closed, not a live price. Prev close 0 · day 0–0 · 52w 0–0 · market cap $0K · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y +0.0% vs S&P 500 +13.4%; 5Y -99.7% vs S&P 500 +76.9%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +0.0% | -99.7% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +0.0% | -68.1% |
| Volatility (annualized) | 0.0% | 440.4% |
| Max drawdown | +0.0% (→) | -100.0% (Oct 2021→May 2024) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 40.7 -3.26% · BHC (Bausch Health Companies Inc.) USD 6.44 -0.77% · HCM (HUTCHMED (China) Limited) USD 14.36 +0.56% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.2 -4.80% · RGC (Regencell Bioscience Holdings L) USD 7.67 -21.81% · LQDA (Liquidia Corporation) USD 42.65 +7.46%

## More
Full page: https://nexqual.com/BSPM · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2013-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |